Analysts have been eager to weigh in on the Healthcare sector with new ratings on Onconova Therapeutics (ONTX), Jazz Pharmaceuticals (JAZZ) and Mersana Therapeutics Inc (MRSN).
Onconova Therapeutics (ONTX)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Onconova Therapeutics, with a price target of $25. The company’s shares closed yesterday at $4.18, close to its 52-week low of $4.16.
Pantginis noted:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $25 price target. Our clinical NPV model, driven by rigostertib in MDS, allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Onconova Therapeutics, Inc.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -18.4% and a 25.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Currently, the analyst consensus on Onconova Therapeutics is a Moderate Buy with an average price target of $20.50, a 390.4% upside from current levels. In a report issued on November 5, Maxim Group also maintained a Buy rating on the stock with a $16 price target.
.
See today’s analyst top recommended stocks >>
Jazz Pharmaceuticals (JAZZ)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Hold rating on Jazz Pharmaceuticals, with a price target of $161. The company’s shares closed yesterday at $150.69.
Livnat wrote:
“Our $161 target (lowered from $167) is based on a DCF which includes an 11% WACC discount rate (from 10%), strong 9.2% 2018-22 cash-flow CAGR, and negative 2% terminal growth beyond 2022 given expected at least modest Xyrem franchise generic headwinds partially offset by other products’ continued growth. Our valuation does not reflect a true generic “cliff” at all. Dramatic generic erosion, which we do not model, would be downside to our valuation. On the other hand, longer Xyrem sustainable growth via life-cycle transition or other barriers to generics could yield material upside to our target.”
According to TipRanks.com, Livnat is a 3-star analyst with an average return of 2.6% and a 49.4% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Agile Therapeutics.
Currently, the analyst consensus on Jazz Pharmaceuticals is a Strong Buy with an average price target of $194.14.
Mersana Therapeutics Inc (MRSN)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Mersana Therapeutics Inc today and set a price target of $23. The company’s shares closed yesterday at $6.04, close to its 52-week low of $5.56.
Chattopadhyay wrote:
“Our 12-month, $23 price target is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF is based on a: beta of 1.55, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.8%, and tax rate of 15% beginning in FY 2027. Our price target leverages the lifting of the partial clinical hold on XMT-1522, based on which we have added the program back into our model, albeit at modest probability of successes, including: (1) 5% POS in HER 1+/2+ breast cancer; and (2) 25% POS in the HER 2+ setting.”
According to TipRanks.com, Chattopadhyay ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.8% and a 34.7% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Jounce Therapeutics Inc.
Mersana Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $21.50, a 256.0% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
